• Product search
Suggested search terms
  • test

Main Research Achievements

We are improving drug efficacy and ease of administration by developing products using our own platform technology (Multi-Layer Capsule Coating Technology) for the development of improved and combined new drugs, providing the driving force to grow into a global company through differentiated research and development.

Current ~ 2010

  • 2019

    Omacor mini soft cap 2g (Licensing date: Jul. 11, 2019)

  • 2018

    Extension of the innovative pharmaceutical company certification

  • 2017

    Launched Rosumega, an incrementally modified drug for treatment of dyslipidemia (registered patent KR 1335365)

    Launched Experid Powder, an incrementally modified drug for treating iron poisoning (registered patent KR 1695970)

  • 2015

    Extention of the innovative pharmaceutical company certification

  • 2014

    Launched Amocla Neo Dry Syrup, an antibiotic composite.

    Launched Circadin, a new drug for treating insomnia.

  • 2012

    Selected as an innovative pharmaceutical company certified by the Ministry of Health and Welfare.

  • 2011

    Kuhnil R&D Center integrated and relocated to the head office.

    (Focusing on R&D with company-wide capabilities in close cooperation with each department, such as sales marketing and medical unit)

2010 ~

  • 2006

    Launched Omacor softgel capsule as a new drug for dyslipidemia treatment.

    Launched Pulmican for treatment of asthma.

  • 2004

    Gasan Digital Complex relocated and name changed (Kuhnil Central R&D Center)

  • 1992

    Established an affiliated research institute (Cheonan).